|
KMID : 0366220140490010015
|
|
Korean Journal of Hematology
2014 Volume.49 No. 1 p.15 ~ p.21
|
|
|
Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma
|
|
Kang Byung-Woog
Sohn Sang-Kyun
Moon Joon-Ho
Chae Yee-Soo
Kim Jong-Gwang
Lee Soo-Jung
Kim Won-Seog
Lee Je-Jung
Lee Se-Ryeon
Park Keon-Uk
Lee Ho-Sup
Lee Won-Sik
Won Jong-Ho
Park Moo-Rim
Kwak Jae-Yong
Kim Min-Kyoung
Kim Hyo-Jung
Oh Sung-Yong
Kang Hye-Jin
Suh Cheol-Won
|
|
|
Abstract
|
|
|
Background: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea.
Methods: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients di-agnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL.
Results: The median age for the patients was 63 years (range, 26?78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involve-ment was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vin-cristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2?77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS.
Conclusion: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.
|
|
|
KEYWORD
|
|
|
Mantle cell lymphoma, Epidemiology, Trend, Survival, Chemotherapy, Rituximab
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|